Furthermore, it may be interesting to further explore the synergistic effect of targeting KIR/NKG2A when chimeric antigen receptors (CARs) are used to redirect and enhance the NK cell anti-tumor response an alternative for ADCC triggering antibodies. Here, KLRC1 is linked to neoplasm.